Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and small molecule discovery and development, announced that it has entered into a collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to develop an investigational antibody drug conjugate (ADC) for the treatment of solid tumors.